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NO news is good news
Thomas L Poulos*, CS Raman and Huiying Li
The recent determination of the crystal structure of
microsomal cytochrome P450 reductase, a diflavin protein
that shuttles electrons from NADPH to the P450 heme,
represents a significant advance towards the
understanding of cytochromes P450. A similar advance
was made in a related enzyme system, nitric oxide
synthase (NOS). The crystal structure of the NOS heme
domain reveals a very different architecture to that
observed in P450s and offers significant insight into the
production of nitric oxide, one of nature’s most important
regulatory molecules.
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In 1992 nitric oxide (NO) was recognized by Science maga-
zine as molecule of the year and shortly before and ever
since, NO was and has become an increasingly popular
target of investigation. Why has such a small molecule
received so much attention? Primarily because of the extra-
ordinary biological effects and medically relevant processes
mediated by NO. NO is at the heart of a number of
complex regulatory mechanisms in the brain, immune, and
cardiovascular systems. In the brain and cardiovascular
systems, NO participates in neurotransmission and vasodi-
lation, respectively. In both systems, NO exerts part of its
effect by binding to the heme of guanyl cyclase which
leads to the production of cyclic GMP (Figure 1). In the
immune system, macrophage cells produce NO as part of
the oxidative cytotoxic arsenal resulting from macrophage
stimulation (i.e. infection). 
Nitric oxide synthase (NOS) is the enzyme responsible for
producing NO. Once the first NOS was sequenced [1] and
the various isoforms recombinantly expressed, progress on
understanding this complex enzyme has been breath-
takingly rapid. So far, three main isoforms of NOS have
been identified corresponding to the three primary physio-
logical processes involving NO: inducible NOS (iNOS,
immune system); neuronal NOS (nNOS); and endothelial
NOS (eNOS, cardiovascular system). All three isoforms
oxidize L-arginine to L-citrulline and NO (Figure 1). The
overall reaction is similar to monooxygenations catalyzed by
cytochromes P450. It is therefore not too surprising that
NOS contains all the components of a P450 mono-
oxygenation system: heme, flavin mononucleotide (FMN),
and flavin adenine dinucleotide (FAD). Unlike P450s,
however, NOS also has tetrahydrobiopterin (BH4) as a
cofactor, the function of which is unknown. In cytochromes
P450, electrons are donated to the P450 heme from
NADPH via a reductase that contains FAD and FMN.
NOS is similar except the flavin reductase is covalently
linked to the heme domain via a linker region that binds
calmodulin (Figure 1). Owing to the linking of the heme
and flavin domains, the various NOS isoforms are large and
range in size from 130 to 160 kDa. The N-terminal domain
of NOS contains the heme-active center where L-arginine
and BH4 bind. While the flavin reductase domain is similar
in sequence to P450 reductase, the NOS heme domain
bears little resemblance in sequence to P450s even though
the NOS heme domain exhibits characteristics strikingly
similar to cytochromes P450. As in P450s, the axial heme
ligand is a cysteine thiolate group and upon reduction of the
heme iron to Fe2+ followed by binding of carbon monoxide,
the absorption spectrum gives a 450 nm band [2–4], a classic
trademark for a P450.
A major advance in understanding NOS, as well as a
further understanding of P450s, has been made recently
owing to the structure determination of the mouse iNOS
heme domain [5] and cytochrome P450 reductase [6]. In
both structures, shorter versions of the enzyme were
used for crystal structure determination. For iNOS, the
heme domain consisting of residues 115–498 was used,
while for P450 reductase the soluble fragment (residues
57–676) missing the N-terminal membrane anchor was
used. As was expected from sequence alignments, the
flavin domain of P450 reductase is structurally similar to
flavodoxins while the FAD–NADPH domain is struc-
turally homologous to ferredoxin reductase. An addi-
tional linker domain connects the FMN and FAD
domains. The flavins are only 4 Å apart which blocks the
edge of FMN that would normally be exposed in flavo-
doxins (Figure 2). Molecular modeling studies between
flavodoxin and various redox partners [7,8] suggested
that electron transfer occurs via the exposed edge of
FMN that is blocked by FAD in P450 reductase. This
raises some interesting possibilities and limitations as to
how the reductase might interact with its various redox
partners like P450, heme oxygenase, and NOS. The pre-
vailing view is that redox partners dock such that the two
redox active prosthetic groups can approach as close as
possible. As the FMN edge is blocked in P450 reductase,
the FMN fi heme electron transfer may require a less
direct route through the protein. Alternatively, the
reductase may undergo a large hinge motion that exposes
the FMN edge enabling a more direct electron path to
the heme. Either possibility is intriguing.
In sharp contrast, the iNOS structure is unique and bears
very little similarity to cytochromes P450 or any other
known heme protein structure (Figure 3). Another heme-
thiolate enzyme, chloroperoxidase (CPO), also exhibits a
unique fold quite different from either NOS or P450 [9].
Nevertheless, the cysteine thiolate environment is highly
conserved (Figure 4). In all three enzymes, the cysteine
sulfur is located near the N-terminal end of a helix (the
proximal helix) where it accepts two hydrogen-bonds
from peptide NH groups. This serves to electrostatically
attenuate the negative charge on the sulfur which, in
turn, increases the redox potential of the heme iron. In
both NOS and P450, the proximal helix is approximately
parallel to the heme plane while in CPO the proximal
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Figure 2
Stereo diagram of cytochrome P450
reductase. The green domain contains the
FAD cofactor and the blue domain the FMN
cofactor. The red domain is the linker
connecting the FMN and FAD domains.
(This figure was generously provided by
JJ Kim, University of Wisconsin, Milwaukee).
Figure 1
Schematic representation of how NOS
functions. NOS is depicted as a homodimer
that dimerizes through the heme domain [10].
An increase in cellular calcium levels stimulates
NOS activity via calcium–calmodulin binding to
NOS which promotes the electron transfer
reaction from the FAD–FMN domain to the
heme-active center. In both the nervous and
cardiovascular systems, NO operates as a
messenger molecule where it stimulates guanyl
cyclase to form cGMP. The role of cGMP in
brain is not well understood but one possibility
is to regulate gated ion channels [11]. In the
cardiovascular system, cGMP regulates protein
kinases leading to vasodilation [12]. In the
immune system NO is not a messenger












































helix is perpendicular to this plane (Figure 4). This orien-
tation may be relevant to how cytochromes P450 interact
with the reductase. The currently favored sight for the
docking of redox partners to P450 is the proximal surface
closest to the cysteine ligand. A parallel proximal helix
would enable a redox partner to approach more closely to
the cysteine ligand than would a proximal helix oriented
perpendicular to the heme. This hints at the possibility
that NOS also uses the proximal surface for interactions
with the reductase. With both the iNOS heme domain
and P450 reductase structures now in hand, molecular
modelers should have some fun trying to ‘stitch’ the two
together to obtain some idea as to how they might inter-
act, with the important restriction that the heme and
flavin domains must be covalently tethered via the
calmodulin binding linker region. 
The real ‘business’ region of NOS is the distal pocket
where the substrates, O2 and L-arginine (and possibly
BH4), bind. The globins, peroxidases, and cytochromes
P450 have a distal helix that runs over the surface of the
heme providing groups that participate in catalysis. The
iNOS heme domain is quite different in having a b -
sheet structure is this region. The iNOS structure shown
in Figure 3 has an imidazole group coordinated to the
heme iron and a substrate analog, aminoguanidine,
bound in a nearby pocket. These interactions are impor-
tant for rational drug design and have some parallels
with the P450s. Nearly all so-called type II P450
inhibitors are double-headed: one region has a hetero-
cyclic N atom directly bound to the iron and the second
region sits in the substrate-binding pocket. This double-
headed structure has been an essential feature in the
design of isoform-specific P450 inhibitors. At the sim-
plest level, the drug designer wants to leave region 1
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Figure 3
Stereo diagram of the mouse iNOS heme
domain. Imidazole is directly coordinated to
the heme iron in the distal pocket. Adjacent to
the imidazole is a molecule of aminoguanidine
that most likely occupies the site for the
guanidinium group of the substrate, L-arginine.
(This figure was generously provided by
J Tainer, The Scripps Research Institute).
Figure 4
A comparison between the cysteine ligand environments in P450 and
chloroperoxidase (CPO). The CPO proximal helix is perpendicular to
the heme while in P450 the helix runs parallel to the heme.
Nevertheless, both cysteine ligands accept hydrogen bonds (dotted
lines) from peptide NH groups near the beginning of the helix. The
hydrogen-bonding environment is the same in NOS. Owing to the
parallel orientation of the helix in P450, the heme is situated closer to
the surface than in CPO. In this orientation, a redox partner could
approach closest to the heme and thiolate ligand from the proximal
side of the heme. The orientation of the helix in NOS is very similar to
that in P450. In all these enzymes, substrates interact with the heme
on the opposite or distal heme surface.
(Figure 5) constant but vary region 2 to be isoform-
specific. The iNOS heme domain structure reveals that
a similar approach should be possible with the various
NOS isoforms. The location of the aminoguanidine
should mimic the binding of the substrate, L-arginine.
The guanidinium group interacts with a glutamate
sidechain that helps position the guanidinium moiety in
position to interact with an iron-linked oxygen atom for
hydroxylation. This arrangement is also very similar to
the way in which cytochromes P450 work, with the
important exception that NOS uses a polar group, gluta-
mate, to bind a polar substrate while the structures of
P450–substrate complexes determined to date indicate
that a preponderance of nonpolar contacts are used to
orient the substrate. 
Despite these important revelations concerning iNOS
architecture, some caution must be exercized in relating
the structure to catalytic function. NOS is active as a
dimer and requires BH4 for full activity. The shortened
version of the iNOS heme domain (missing residues
1–114) used for the structure determination does not
dimerize nor does this truncated version interact with
L-arginine or BH4 [10]. Therefore, it appears that the
missing residues in the iNOS structure are critical to the
formation of a dimer and a functional active site required
for the binding of L-arginine and BH4 [10]. As a result, the
iNOS heme domain structure must be used with caution
for understanding the catalytic mechanism and for rational
drug design. Nevertheless, the new iNOS heme domain
structure has provided a major step forward in understand-
ing a complex and fascinating enzyme, while the P450
reductase structure has given a major boost to understand-
ing the illusive electron transfer mechanism involved in
the P450 catalytic cycle. 
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Figure 5
Binding mode of inhibitors and drugs to P450 or NOS. One goal in
drug design is to keep region 1 constant for blocking access to the
heme iron but to design region 2 to be isoform-specific (see text for
details).
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